Kathryn Guarini Biography and Net Worth

Dr. Guarini has been a director of the company since 2023, joining the company after serving as Chief Information Officer of IBM from 2021 to 2023 with specific focus on information technology, data security and artificial intelligence. Prior to assuming her role as CIO, Dr. Guarini served in multiple executive leadership roles at IBM over more than 20 years, including Chief Operating Officer of IBM Research and Vice President of Product Management for IBM Systems. Dr. Guarini has been included on the Top 100 Leader list (#2 in 2022) from Technology Magazine and Forbes’ CIO Next list (2022), and she is a member of the United States Patent & Trademark Office’s National Council for Expanding American Innovation. She earned her Bachelor of Science and Ph.D. in Applied Physics from Yale University and Stanford University, respectively.

What is Kathryn Guarini's net worth?: The estimated net worth of Kathryn Guarini is at least $485.98 thousand as of August 10th, 2026. Guarini owns 603 shares of Regeneron Pharmaceuticals stock worth more than $485,976 as of August 17th. This net worth estimate does not reflect any other investments that Guarini may own. Learn More about Kathryn Guarini's net worth.
How do I contact Kathryn Guarini?: The corporate mailing address for Guarini and other Regeneron Pharmaceuticals executives is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. Regeneron Pharmaceuticals can also be reached via phone at (914) 847-7000 and via email at [email protected]. Learn More on Kathryn Guarini's contact information.
Has Kathryn Guarini been buying or selling shares of Regeneron Pharmaceuticals?: During the last ninety days, Kathryn Guarini has sold $320,000.00 of Regeneron Pharmaceuticals stock. Most recently, Kathryn Guarini sold 400 shares of the business's stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a transaction totalling $320,000.00. Following the completion of the sale, the director now directly owns 603 shares of the company's stock, valued at $482,400. Learn More on Kathryn Guarini's trading history.
Who are Regeneron Pharmaceuticals' active insiders?: Regeneron Pharmaceuticals' insider roster includes Bonnie Bassler (Director), Michael Brown (Director), N. Coles (Director), Christopher Fenimore (VP), Joseph Goldstein (Director), Kathryn Guarini (Director), Robert Landry (CFO), Joseph Larosa (EVP), Marion Mccourt (EVP), Andrew Murphy (EVP), Jason Pitofsky (VP), Christine Poon (Director), Arthur Ryan (Director), Leonard Schleifer (CEO), George Sing (Director), Neil Stahl (EVP), Marc Tessier-Lavigne (Director), P. Vagelos (Director), Daniel Van Plew (EVP), George Yancopoulos (Insider), and Huda Zoghbi (Director). Learn More on Regeneron Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Regeneron Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 13,705 shares worth more than $9,836,813.59. The most recent insider tranaction occured on August, 10th when Director Kathryn Guarini sold 400 shares worth more than $320,000.00. Insiders at Regeneron Pharmaceuticals own 7.0% of the company. Learn More about insider trades at Regeneron Pharmaceuticals.
Information on this page was last updated on 8/10/2026.

Kathryn Guarini Insider Trading History at Regeneron Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/10/2026	Sell	400	$800.00	$320,000.00	603

Kathryn Guarini Buying and Selling Activity at Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Company Overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Today's Range

Now: $805.93

$795.73

$813.18

50 Day Range

MA: $675.79

$601.65

$808.05

2 Week Range

Now: $805.93

$541.00

$821.11

Volume

541,290 shs

Average Volume

853,534 shs

Market Capitalization

$82.98 billion

P/E Ratio

19.92

Dividend Yield

0.47%

Beta

0.21